Sorrento Therpt (SRNE)
$10.78 1.02 (10.45%)
19:59 EDT SRNE Stock Quote Delayed 30 Minutes
Previous Close $10.78
Market Cap 1.25B
PE Ratio 53.90
Volume (Avg. Vol.) 60.58M
Day's Range 9.32 - 11.15
52-Week Range 1.39 - 19.39
Dividend & Yield N/A (N/A)
SRNE Stock Predictions, Articles, and Sorrento Therpt News
- From InvestorPlace
- From the Web
The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.
By Thomas Niel
So, what's the call here? If you have a high risk tolerance, and are looking for a short-term pandemic play, SRNE stock today may be worth the risk. Just don't bet the ranch.
Sorrento has some potential positive catalysts, especially its Covid-19 diagnostic test. But SRNE stock is really just for the speculative part of your portfolio.
Lack of a track record, a lagging Covid-19 test project and executive turmoil make SRNE stock a coronavirus play to avoid.
Sorrento Therapeutics just announced plans to launch human trials of its antibody drug. Here's why else SRNE stock is rallying.
Already in financial distress, SRNE stock has too much riding on a Covid-19 spit test that lags far behind one released by Yale University.
Sorrento Therapeutics has lost 44% since firing its chief financial officer on Aug. 19. Is SRNE stock a buy given its drop in recent days?
Sorrento Therapeutics looks overvalued here. Investors in SRNE stock can expect dilution from equity/debt raises, given the company's ongoing burn rate and deals.
SRNE stock was one of the top performers of this year. But just as quickly, shares have faded, and I'm not sure its Covid-19 pipeline will pan out.
SRNE stock has been the target of a so-called "bear raid." But shorts make good points, and red flags remain for Sorrento.
SRNE stock is 60% off its highs, but such is the nature of these stocks. They are always one headline away from greatness.
If some of its Covid-19 pipeline hits it big, SRNE stock will reward your faith handsomely -- but it's a big 'if.'
Sorrento's COVID-19 test appears to be superior to competing diagnostics, and it just made a good acquisition, while its overall strategy is sound.
Sorrento Therapeutics is in a massive war of words with short sellers such as Hindenburg Research. And for now, SRNE stock bears are winning.
Even a vaccine that's 50% effective with some side effects would be a game changer. The Trump Administration is throwing billions into that hope and investors are seeing big profits.
SRNE stock has a lot of potential but with the clinical prematurity of its product base it's difficult to invest in Sorrento at this time.
While SRNE stock is likely to be volatile in the near term, the firm's diagnostic tests look like some of the best options on the market making it a good coronavirus play
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader